Moderna Shares Fall Despite Positive Cancer Vaccine Trial Results
Moderna shares dropped after the company released detailed cancer vaccine trial results showing a 42% reduction in melanoma recurrence risk. Despite the positive data, investors engaged in profit-taking due to concerns about commercial prospects, regulatory approval timelines, and future opportunities in oncology. The market reaction reflects cautious optimism about the vaccine's potential.
ET Markets·



